Unlearn’s use cases demonstrate how AI-generated digital twins optimize clinical trials

SAN FRANCISCO: Unlearn, an artificial intelligence (AI) company today announced two poster sessions at the Alzheimer's Association International Conference (AAIC) in Philadelphia: “Accelerating randomized clinical trials in Alzheimer’s Disease using generative machine learning model forecasts of progression” (Poster #86486) with Johnson & Johnson Innovative Medicine; and “Assessment of AI-generated digital twin methodology on reduction of treatment effect variance and potential clinical trial sample size saving using a phase 2 trial dataset from patients with Alzheimer’s disease” (Poster #90685) with AbbVie.

In each poster, Unlearn presents its work using disease-specific AI models called Digital Twin Generators that create digital twins of clinical trial participants. Digital twins are forecasts of individual participants’ control outcomes and are used to increase power and reduce control arm sizes in randomized clinical trials.

SUMMARY WITH J&J INNOVATIVE MEDICINE: Unlearn demonstrates the application of its technology retrospectively on three pivotal Phase III clinical trials in mild-to-moderate AD. They show how incorporating participants’ digital twins in clinical trials can reduce control arm sizes by 33% when estimating the treatment effect on ADAS-Cog11 at 18 months or by 19% when estimating the treatment effect on CDR-SB at 12 months in Phase 3 studies. Alternatively, digital twins can be used to achieve power gains of up to 10% (from 80% to up to 90%) with ADAS-Cog11.

SUMMARY WITH ABBVIE: Unlearn shows how leveraging participants’ digital twins can reduce overall sample sizes by 10-15% when estimating the treatment effect on CDR-SB at week 96 in a Phase 2 study. Alternatively, digital twins can achieve power gains of up to 7% (from 80% to up to 87%) with CDR-SB.

Additional Resources:

• For more information on Unlearn’s Digital Twin Generators for Alzheimer’s Disease, click here.
• Learn more about Unlearn’s vision for the future of AI in medicine here.
• Connect with Unlearn on LinkedIn and X/Twitter.
• To learn more about AAIC, visit aaic.alz.org.

ABOUT: Unlearn is a pioneering artificial intelligence research company that is revolutionizing clinical research with computational models of patients called digital twins. Digital twins provide forecasts of an individual’s health outcomes. They are used in the Unlearn Platform to help pharmaceutical and biotech companies optimize clinical development and quickly and confidently produce trustworthy outcomes.

Fonte: Business Wire